Circulating adiponectin levels are decreased in obesity, diabetes, the metabolic syndrome, and atherosclerosis, and there is now convincing evidence for adiponectin to exert multiple protective effects in metabolic liver diseases [79]. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.